International Flavors & Fragrances Inc.

(New York Stock Exchange)
Back to all articles
Slightly Bullish +25

International Flavors Gears Up to Report Q1 Earnings: What's in Store?

AI-generated analysis

International Flavors & Fragrances Inc. (IFF) is scheduled to report its first-quarter 2026 earnings on May 5 after the closing bell.

Analysts expect sales to reach $2.65 billion, representing a 6.7% decline from the year-ago period.

The consensus earnings estimate stands at $1.08 per share, which marks a 10% year-over-year decrease.

Zacks Investment Research maintains a Zacks Rank #3 (Hold) for IFF, though their model currently predicts an earnings beat.

IFF's Earnings ESP of +2.09% suggests positive sentiment ahead of the report based on recent performance patterns.

The company has seen volume growth across all businesses and implemented productivity improvements to reduce costs.

However, rising raw material prices along with increased labor, shipping, and cleaning expenses are expected to pressure margins.

Following segment restructuring in 2025, IFF now operates four divisions: Taste, Food Ingredients, Health & Bioscience, and Scent.

The Taste segment is projected to post $649 million in sales (3.5% growth) and $139 million in adjusted operating EBITDA.

Food Ingredient sales are estimated at $797 million with a 0.1% increase, while Health & Bioscience revenue is forecast at $558 million.

Scent segment revenue is expected to rise 3.7% to $637 million, supported by momentum in consumer and fine fragrances.

IFF shares have underperformed relative to the industry by 8.4% over the past year, contrasting with broader sector gains.

The article also highlights other Basic Materials stocks like CF Industries and Albemarle that are anticipated to beat earnings expectations.

Bullish Signals
  • Zacks model predicts an earnings beat for International Flavors, supported by a positive Earnings ESP of +2.09%.
  • The company holds a Zacks Rank of 3 (Hold), which increases the odds of achieving a positive earnings surprise.
  • Historically, International Flavors has beaten Zacks Consensus Estimates in three of the trailing four quarters with an average beat of 1.9%.
  • Volume growth is observed across all business divisions, indicating broad-based operational strength.
  • Taste segment sales are projected to rise 3.5% year-over-year to $649 million with adjusted operating EBITDA growing 6.4% to $139 million.
  • Scent segment sales are estimated to increase 3.7% year-over-year, driven by ongoing momentum in Consumer Fragrance and Fragrance Ingredients.
  • The Health & Biosciences segment shows robust upside with projected operating EBITDA increasing a strong 22.3% to $169 million.
  • The Scent segment's estimated quarterly operating EBITDA is projected to rise 9.5% year-over-year to $158 million.
Risk Factors
  • The company is expected to see a 6.7% dip in sales, with the consensus estimate pegged at $2.65 billion compared to year-ago figures.
  • Earnings estimates indicate a year-over-year decline of 10%, with the Zacks Consensus Estimate pegged at $1.08 per share.
  • IFF has incurred high raw material costs, along with additional expenses related to labor, shipping, and cleaning, which are expected to dent its margins despite pricing actions.
  • The company's shares have lost 8.4% over the past year, significantly underperforming against the industry's 7% growth, the Basic Materials sector's 43.1% jump, and the S&P 500's 34% increase.
  • Gains in the Scent segment may be partially negated by higher costs despite ongoing momentum in consumer fragrance and ingredients.
  • The article notes that IFF is scheduled to report earnings after the closing bell on May 5, following a period of underperformance relative to broader market indices.
Full Analysis
International Flavors & Fragrances Inc. (IFF) is scheduled to report its first-quarter 2026 earnings results on May 5, following the closing bell. Analysts from Zacks predict consolidated sales of $2.65 billion, representing a 6.7% decline compared to the year-ago period, while consensus earnings estimates stand at $1.08 per share, unchanged over the past 60 days and indicating a 10% year-over-year drop. The company recently divested its Pharma Solutions segment in May 2025 and restructured its portfolio into four divisions: Taste, Food Ingredients, Health & Bioscience, and Scent, reflecting operational adjustments made at the start of Q1 2025. Segment-level projections suggest mixed performance across IFF's business units for the upcoming quarter. The Taste segment is estimated to report sales growth of 3.5% year over year to $649 million, with adjusted operating EBITDA rising 6.4% to $139 million. Food Ingredients sales are forecasted to inch up 0.1% to $797 million, with adjusted operating EBITDA increasing 6.3% to $118 million. The Scent segment is expected to see a 3.7% sales rise to $637 million driven by momentum in consumer and fine fragrances, while Health & Biosciences projects sales growth of 3.3% to $558 million with a significant 22.3% jump in adjusted operating EBITDA to $169 million. Despite volume growth and productivity improvements, IFF's margins face headwinds from high raw material costs as well as elevated expenses related to labor, shipping, and cleaning. Historically, IFF has beaten earnings estimates in three of the last four quarters with an average surprise of 1.9%, yet its shares have underperformed the industry, losing 8.4% over the past year against a 7% industry gain, while the broader Basic Materials sector rose 43.1% and the S&P 500 gained 34%. Zacks Investment Research's model currently gives IFF a Rank of 3 (Hold) with an Earnings ESP of +2.09%, indicating a predicted earnings beat based on their analytical framework.